Back to journals
Academic Journal

Depression and Anxiety

4 Papers Indexed in Blossom

Data updated

Research Footprint

Depression and Anxiety has 4 tracked papers indexed in Blossom (2016–2021) from 38 authors, most often covering Ketamine, Esketamine and Placebo, across Anxiety Disorders, Depressive Disorders and Major Depressive Disorder (MDD).

Published Papers

Open Accessindividual

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder

This post-approval, double-blind, placebo-controlled study (n=223, TRANSFORM-2) finds that those with comorbid anxiety (72%) responded just as well as those without anxiety to esketamine (56-84mg, 4 weeks, combined with SSRI) treatment.

Published
Journal
Depression and Anxiety
Authors
Daly, E. J., Turkoz, I., Salvadore, G., Fedgchin, M., Ionescu, D. F., Lynn Starr, |. H., Borentain, S., Trivedi, M. H., Thase, M. E., Singh, J. B.
Open Accessmeta

Historic psychedelic drug trials and the treatment of anxiety disorders

This meta-review (2019) examined the efficacy of psychedelics combined with therapy for the treatment of anxiety disorders, across twenty studies conducted between 1940 to 2000. The review outlines individual aspects of their design, assessment methodology, and notable shortcomings, such as the lack of randomised control designs and overreliance on the therapists' opinion. The large majority of patients of these studies exhibited improved symptoms over the course of treatment with psychedelic-assisted therapy.

Published
Journal
Depression and Anxiety
Authors
Weston, N. M., Gibbs, D., Bird, C. I. V., Daniel, |. A., Jelen, L. A., Knight, G., Goldsmith, D., Young, A. H., Rucker, J. J., Daniel, A.
Open Accessindividual

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression

This multisite, double-blind, placebo-controlled study (n=99) evaluated the effect of ketamine (3.5 -; 35 mg/70kg) versus midazolam (3.15 mg/70kg) in anxious versus non-anxious unipolar treatment-resistant depression (TRD). The pilot results concluded that there was no significant effect found between both groups. In contrast to traditional antidepressants, the effects of ketamine may be similar in both anxious and non-anxious TRD subjects.

Published
Journal
Depression and Anxiety
Authors
Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoeppner, B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., Debattista, C., Ionescu, D. F., Papakostas, G. I.
Open Accessmeta

Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice

This review (2016) examines the clinical efficacy of ketamine as fast-acting pharmacotherapy for major depressive disorder and bipolar disorder (BP), in light of the available evidence. In the authors' view, there is insufficient empirical support for the early adoption of ketamine into routine practice, given the lack of data on the longer-term safety of ketamine as an antidepressant therapy, which will require the development of clinical protocols with standardized screening, clinical phenotyping, and follow-up procedures.

Published
Journal
Depression and Anxiety
Authors
Bobo, W. V., Vande Voort, J. L., Croarkin, P. E., Leung, J. G., Tye, S. J., Frye, M. A.

Quick Facts

Papers Indexed
4
h-Index
168
Open Access
No
Publisher
Wiley
Country
United States
Website
Visit